- Conference Call Scheduled for February 25, 2009, 5:00 p.m. U.S. ET -
EXTON, Pa., Feb. 18 /PRNewswire-FirstCall/ -- Adolor Corporation today announced that it will hold a conference call at 5:00 p.m. ET on Wednesday, February 25, 2009 to discuss fourth quarter and year end financials and an update on the launch of ENTEREG(R) (alvimopan).
To participate in the audio portion and have the opportunity to pose questions, dial (866) 394-4329 for domestic callers, or (706) 902-1952 for international callers, and enter Conference ID # 85748128. Investors also can listen to the call live by logging on to the Company’s website at www.adolor.com and clicking on “Investor Insights,” then “Calendar of Events.”
A replay of the call will be available beginning approximately two hours after the event. To listen to a replay of the conference call, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter Conference ID # 85748128 or listen via Adolor’s website. The replay will be available for one week.
About Adolor Corporation
Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.
Adolor’s first approved product in the United States is ENTEREG(R) (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the Entereg Access Support and Education (E.A.S.E.) Program. In collaboration with GlaxoSmithKline, the company launched ENTEREG in mid-2008. For more information, visit www.adolor.com.
CONTACT: Stephen W. Webster, Senior Vice President, Finance and CFO of
Adolor Corporation, +1-484-595-1500; or Media, Mike Beyer of Sam Brown,
Inc. for Adolor Corporation, +1-773-463-4211
Web site: http://www.adolor.com/
